PPT-FDA Approved Cannabis Products

Marinol and Syndros synthetic THC Max daily 20mg168mg and Cesamet THC analog anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome AIDS nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments . Dr. Bareket Schiff Keren. Some history. GLOBAL. AND. LOCAL. Gan. -. zi. -gun-nu. – the drug that takes away the mind. Azallu. . – hand of ghost, poison of all limbs. (neurological diseases?). Professor Les Iversen. University of Oxford. Female Cannabis Flower. William O’Shaughnessy – a Victorian Genius. 1832. – (age 22) . idea for fluid/electrolyte replacement in cholera. 1833. -Joined East India Company in Calcutta as physician, surgeon, professor of Chemistry and scientist –validated folk use of cannabis. U.S. Federal Patent. http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6630507.PN.&OS=PN/6630507&RS=PN/6630507. September 2016. Implementation Timeline. Office of Compassionate Use Established. : July 1, 2014. Florida Administrative Code Chapter 64-4 Promulgated, Final Rule Upheld: . May 28, 2015. Dispensing Organization Applications Accepted: . HIGHLY . PROFITABLE PLATFORM . POISED FOR GROWTH. FORWARD LOOKING STATEMENTS. This presentation . includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Transaction and BCC's objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in BCC's public documents filed on SEDAR at . Victoria. Dr. Daniel Perkins. Manager Research Strategy and Policy. Office of Medicinal Cannabis. Department of Health and Human Services Victoria. Cannabis regulatory framework. Victorian reform. December . Environmental. . Health. Swati . Bhatt,. . Manager. Specialized . Surveillance and. Enforcement. Department . of Public. . Health. STATE’S . REGULATORY. . FRAMEWORK. Year. Regulation. Description. Dra. Leticia Cuñetti. June 2018. . I declare that I have no conflicts of interest to make this presentation.. . . Dra. Leticia Cuñetti . Delmonte. June 2018. Chronic pain is a major therapeutic problem in patients with kidney transplant due to the nephrotoxicity of NSAIDs. Dra. Leticia Cuñetti. June 2018. . I declare that I have no conflicts of interest to make this presentation.. . . Dra. Leticia Cuñetti . Delmonte. June 2018. Chronic pain is a major therapeutic problem in patients with kidney transplant due to the nephrotoxicity of NSAIDs. Objectives. Explain the history of CBD and Hemp. Discuss cannabis-based approved medications in the US. Explore the marketing and efficacy of CBD. Discuss the legality of the use of CBD in the nation. Amnesia Haze Strain Review: Description, Effects and Flavors Strain Review: Lemon Haze Learning Objectives. Summarise regulatory changes and other issues that need to be considered for the legal use and supply of medicinal cannabis . Discuss the Commonwealth and state specific requirements to prescribe and dispense medicinal cannabis in Australia. DRAFT--FOR DISCUSSION PURPOSES ONLY. This presentation has not been reviewed or approved by the Cannabis Control Commission.. Public Commission Meeting.  . Wednesday, . January . 17, . 2018. 10:30 AM.